WHERE DOES THE MONEY GO?
RallyforRhyan donates the money it raises to pediatric cancer research studies and other initiatives that assist families fighting this horrible disease. To date, RallyforRhyan has distributed over $800,000! We have contributed to many different organizations, listed below are examples of three studies that RallyforRhyan helped fund.
Study Name: Phase I Study of Hu3F8 with Donated Natural Killer Cells to Treat Recurrent or Persistent Neuroblastoma
Research Hospital: Memorial Sloan Kettering Cancer Center
Lead Researcher: Dr. Shakeel Modak
Purpose: The goal of this study is to see if it is safe and feasible to give Hu3F8, chemotherapy (cyclophosphamide) and natural killer (NK) cells from a mismatched donor. Patients also receive a treatment celled interleukin-2 (IL-2), which stimulates NK cells to grow and survive.
Study Name: ALK Phase 1 Clinical Trial
Lead Researcher: Dr. Yael Mosse'
Research Hospital: Children's Hospital of Philadelphia
Purpose: To study the effects of the lung cancer drug Crizotinib on ALK mutations, which is present in Neuroblastoma and Lymphoma genes. This is a pill designed to zero in on abnormal genes that drive specific cancers. It has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, and in children with a rare form of neuroblastoma.
* donation made in conjunction with Braden's Hope out of Kansas City
Other Organizations to Receive RallyforRhyan Donations:
National Children's Cancer Society
American Cancer Society
Ronald McDonald House of NYC
Ronald McDonald House of Memphis
Ronald McDonald House of Columbia, MO
Band of Parents
MU Children's Hospital
St. Jude
Nationwide Children's Hospital
Lizzie's Walk of Faith
Study Name: Transjoin Therapy
Lead Researcher: Tim Cripe
Research Hospital: Nationwide Childrens Hospital
Purpose: TransJoin is part of a new and groundbreaking class of therapeutic agents known as “gene therapy;” rather than being a discrete drug in itself, TransJoin can instead be thought of as a set of blueprints that the patient’s body can follow to continually synthesize new anti-cancer therapy. This allows TransJoin to constantly be on the attack against neuroblastoma cancer cells, helping to keep the primary tumor in check and preventing it from spreading further.
